26.06.2012 • NewsappointmentsSiegfriedPeople

Siegfried Appoints René Imwinkelried Head of R&D

The Board of Directors of Siegfried Holding appointed René Imwinkelried, Ph.D., the company's new Head Research & Development and member of the Executive Committee. He is currently Head of Technical Development Small Molecules at Roche in Basel. René Imwinkelried will start in his new function on September 1st, 2012.

He succeeds Wolfgang Wienand, Ph.D., who held this position since August 2010 and will now focus on further developing Strategy and Mergers & Acquisitions in the Executive Committee and on his responsibility for Legal and IP Management. Wolfgang Wienand will continue to execute both functions until René Imwinkelried joins Siegfried.

For personal reasons, Beat In-Albon, Ph.D., has with immediate effect resigned from the Board of Directors of Siegfried Holding.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read